EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension

Justus G Garweg, Varun Chaudhary, Xin Zhang, Sergio Leal, Tobias Machewitz, Marion R Munk, Javier Zarranz-Ventura, Andreas Stahl, Paolo Lanzetta, PULSAR Study Investigators

Ophthalmology Retina · 2026-11 · 10 (11) · 1100-1110

DOI: 10.1016/j.oret.2026.06.032 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2026-11. Verfasst von Justus G Garweg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland; Department of Ophthalmology, Inselspital (Bern Univ…. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Visual Acuity, Wet Macular Degeneration. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG, Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVisual AcuityWet Macular DegenerationHumansDouble-Blind MethodFemaleMaleIntravitreal InjectionsDose-Response Relationship, DrugAngiogenesis InhibitorsTreatment OutcomeFollow-Up StudiesAgedTomography, Optical CoherenceFluorescein AngiographyTime FactorsDrug Administration ScheduleFundus Oculi

Stichwörter der Autor:innen

AfliberceptBaseline characteristicsDose regimen modificationDosing intervalNeovascular age-related macular degeneration.

Substanzen

afliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland; Department of Ophthalmology, Inselspital (Bern University Hospital), University of Bern, Bern, Switzerland. Electronic ad…
  • Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
  • Bayer Consumer Care AG, Basel, Switzerland.
  • Bayer AG, Berlin, Germany.
  • Augenarzt-Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; Department of Ophthalmology, Inselspital (Bern University Hospital), University of Bern, Bern, Switzerland; Department of Ophthalmology, Feinberg School…
  • Hospital Clínic de Barcelona, Barcelona, Spain; Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.

Förderung

  • Bayer AG
  • Regeneron Pharmaceuticals Inc

Zitieren

APA

Garweg, J. G., Chaudhary, V., Zhang, X., Leal, S., Machewitz, T., Munk, M. R., Zarranz-Ventura, J., Stahl, A., Lanzetta, P., & PULSAR Study Investigators (2026). Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension. Ophthalmology Retina, 10(11), 1100-1110. https://doi.org/10.1016/j.oret.2026.06.032

Vancouver

Garweg JG, Chaudhary V, Zhang X, Leal S, Machewitz T, Munk MR, et al. Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension. Ophthalmology Retina. 2026;10(11):1100-1110. doi:10.1016/j.oret.2026.06.032

BibTeX
@article{Garweg2026,
  author = {Garweg, Justus G and Chaudhary, Varun and Zhang, Xin and Leal, Sergio and Machewitz, Tobias and Munk, Marion R and Zarranz-Ventura, Javier and Stahl, Andreas and Lanzetta, Paolo and PULSAR Study Investigators, PULSAR Study Investigators},
  title = {Effect of Key Baseline Disease Characteristics on Aflibercept 8 mg Dosing Interval Extension},
  journal = {Ophthalmology Retina},
  year = {2026},
  volume = {10},
  number = {11},
  pages = {1100--1110},
  doi = {10.1016/j.oret.2026.06.032}
}
Kostenlos starten →